=> d l1
L1 HAS NO ANSWERS
L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE

=> s l1 ful
FULL SEARCH INITIATED 17:11:12 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2102 TO ITERATE

100.0% PROCESSED 2102 ITERATIONS 60 ANSWERS
SEARCH TIME: 00.00.01

L3 60 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 179.74 179.95

FILE 'CAPLUS' ENTERED AT 17:11:16 ON 09 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 9 Oct 2008 VOL 149 ISS 15
FILE LAST UPDATED: 8 Oct 2008 (20081008/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l3
L4 2 L3

=> d bib abs 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:14393 CAPLUS
DN 142:113910
TI Preparation of aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists
IN Bosmans, Jean-Paul Rene Marie Andre; Gijsen, Henricus Jacobus Maria; Mevellec, Laurence Anne
PA Janssen Pharmaceutica N.V., Belg.
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005000837	A1	20050106	WO 2004-EP6280	20040610
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004251823	A1	20050106	AU 2004-251823	20040610
	CA 2526079	A1	20050106	CA 2004-2526079	20040610
	EP 1641783	A1	20060405	EP 2004-739781	20040610
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2007526875	T	20070920	JP 2006-515884	20040610
	US 20060142339	A1	20060629	US 2005-560300	20051212
PRAI	EP 2003-50238	A	20030619		
	WO 2003-EP50238	A	20030619		
	WO 2004-EP6280	W	20040610		

OS MARPAT 142:113910
GI



I



II

AB Novel compds. of formula I [X = O(CH2)nO, O(CH2)n; n = 1-5; R3 = H, halo, alkyl, alkoxy; R4 = H, halo, alkyl, alkoxy, cyanoalkyl, CN, (substituted) amino; R5 = H, alkyl; L = (substituted) aminosulfonylalkyl, alkylsulfonylaminocarbonylalkyl, etc.] are prepared which have 5HT4-antagonistic properties. The invention further relates to methods for preparing such compds., pharmaceutical compns. comprising said compds. as well as the use as a medicine of said compds. Thus, II was prepared, and had 5HT4 antagonism activity with pIC50 of 7.92, and was 5% metabolized after 60 min in liver tissue.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2000:191083 CAPLUS
DN 132:237098
TI Preparation of dihydrobenzodioxine carboxamide and ketone derivatives as 5-HT4 receptor antagonists
IN Clark, Robin Douglas; Jahangir, Alam
PA F. Hoffmann-La Roche A.-G., Switz.
SO PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000015636	A1	20000323	WO 1999-EP6402	19990901
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2340952	A1	20000323	CA 1999-2340952	19990901
AU 9958572	A	20000403	AU 1999-58572	19990901
AU 758807	B2	20030327		
BR 9913542	A	20010605	BR 1999-13542	19990901
EP 1112270	A1	20010704	EP 1999-946076	19990901
EP 1112270	B1	20070321		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, CY

	TR 200100698	T2	20010723	TR 2001-698	19990901
	JP 2002524561	T	20020806	JP 2000-570174	19990901
	JP 3366323	B2	20030114		
	AT 357443	T	20070415	AT 1999-946076	19990901
	ES 2283132	T3	20071016	ES 1999-946076	19990901
	US 6172062	B1	20010109	US 1999-392195	19990902
	MX 2001PA02237	A	20010528	MX 2001-PA2237	20010301
	ZA 2001001833	A	20020605	ZA 2001-1833	20010305
PRAI	US 1998-99740P	P	19980910		
	US 1999-138468P	P	19990610		
	WO 1999-EP6402	W	19990901		

OS MARPAT 132:237098

GI



I

Q=



Q1=



AB 5-HT4 receptor antagonist compds. I [Z = Q, Q1; R1, R2 = H, alkyl, alkoxy, halo, amino, OH; X = NH, CH2; m = 2-4; Y = SO2; R3, R4, R5 = H, alkyl; Q = O, S, NR6, CR7R8; n = 1, 2] were prepared E.g., 2,3-dihydrobenzo[1,4]dioxin-5-carboxylic acid (1-{3-[(4-fluorophenyl)piperazine-1-sulfonyl]propyl}piperidin-4-ylmethyl)amide was prepared

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d hitstr 2

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

IT 261766-95-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dihydrobenzodioxine carboxamide and ketone derivs. as 5-HT4 receptor antagonists)

RN 261766-95-4 CAPLUS

CN 1,4-Benzodioxin-5-carboxamide, 2,3-dihydro-N-[[1-[3-[[methyl(1-methyl-4-piperidinyl)amino]sulfonyl]propyl]-4-piperidinyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● HCl